Vascular adverse events under long-term nilotinib therapy in patients with chronic myeloid leukemia
Publication date: Available online 1 August 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Ahmet Emre Eskazan (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 1, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon
Conclusion In our study population, the achievement of a MMR and CCyR and overall survival, progression-free survival, and event-free survival were similar to previous published data. Reaching high survival rates with a first-generation TKI in a country with limited resources is a reasonable treatment approach for CML patients. Micro-Abstract In the 2000s, the introduction of the tyrosine kinase inhibitor, imatinib, improved the survival outcomes of patients with chronic myeloid leukemia (CML). In Lebanon, we rapidly adopted this treatment strategy. We retrospectively reviewed the medical records of 46 patients diagnosed w...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Zaher K. Otrock, Naval Daver, Charles S. Eby Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by excessive activation of the immune system, resulting in overproduction of inflammatory cytokines. Patients usually present with high fever, cytopenias, hyperferritinemia, and hepatosplenomegaly, and their disease process ranges from mild to fatal multiorgan failure. HLH is a heterogeneous group of disorders that can be triggered by infections, neoplasms, or autoimmune diseases. The HLH diagnosis can b...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Management of Patients With Histologic Transformation
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Nishitha M. Reddy The incidence of histological transformation is up to 30% over a period of 10 years. This risk persists even beyond the initial decade of diagnosis of an indent lymphoma. In this era of emerging novel therapies, one could hope for an improved survival. There are currently no randomized trials guiding therapy for transformed lymphoma. Treatment recommendations are based on observational studies or non-randomized single arm clinical trials. To that extent, although routinely recommended and performed...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Ashley D. Staton, Amelia A. Langston Mantle cell lymphoma is a relatively rare malignancy, comprising fewer than 10% of all non-Hodgkin lymphomas. It is a heterogeneous disease, and although most patients experience an aggressive clinical course, some have a more indolent disease and may not require immediate therapy. There are currently few reliable prognostic markers, making it difficult to accurately predict which patients require early intensive treatment. We argue that consolidative autologous stem cell transpl...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Real-life Experience for Integration of PET-CT in  the Treatment of Hodgkin Lymphoma in Lebanon
Conclusion Functional imaging techniques are increasing in popularity compared with anatomic imaging. The usage of PET-CT has emerged as a highly valuable staging and follow-up method in the treatment of HL 8 years after the introduction of PET in Lebanon. PET was used first to improve the staging, then to evaluate the treatment response, and, recently, to tailor therapy according to the response. Micro-Abstract Hodgkin lymphoma (HL) is a highly curable disease. We analyzed the data regarding the usage of PET-CT at diagnosis, during treatment (interim PET), and at the end of treatment. The first PET-CT system was introduce...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Survival Pattern of Hodgkin Lymphoma Patients in the Last 25 Years in Lebanon
Conclusion The survival of patients with HL has dramatically improved over the past 25 years in Lebanon. These results resemble those achieved in Western countries due to the fast adoption of new molecular imaging technologies at diagnosis and follow-up and the rapid approval of new drugs for relapse in the Lebanese market. Micro-Abstract We retrospectively compared the overall survival in HL over 3 different decades in Lebanon. Patients were divided into 3 groups according to period of analysis: group A (1990-1999), group B (2000-2009), and group C (2010-2015). The survival rate at 5 years in group A was 91%, 94% in group...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

High-risk Multiple Myeloma: Definition and Management
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Nisha S. Joseph, Silvia Gentili, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka The prognosis of patients with multiple myeloma has significantly improved after the introduction of novel concepts of immunomodulation and proteasome inhibition in myeloma therapies. In conjunction with the use of high-dose therapy and autologous stem cell transplantation, these newer antimyeloma agents facilitated the augmentation of deeper responses and as a result, enhanced survival outcomes. Despite mounting clinical evidence that...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Treatment Choices: A Quality of Life Comparison in Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Conclusion The study participants treated with inpatient, induction chemotherapy experienced statistically significant improvement in their quality of life at 1 month. The outpatient, nonintensive study participants had stable quality of life at 1 month. Micro-Abstract The results of the present pilot study can be used to counsel older patients with acute myeloid leukemia and high-risk myelodysplastic syndrome regarding treatment choices that will align with their goals for their quality of life. Future studies are needed with a larger and more diverse patient sample to address whether the more intensive treatment approach...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Umang Patel, Rajyalakshmi Luthra, L. Jeffrey Medeiros, Keyur P. Patel The classification and risk stratification of myeloid neoplasms, including acute myeloid leukemia, myelodysplastic syndromes, myelodysplastic syndromes/myeloproliferative neoplasms, and myeloproliferative neoplasms, have increasingly been guided by molecular genetic abnormalities. Gene expression analysis and next-generation sequencing have led to the ever increasing discovery of somatic gene mutations in myeloid neoplasms. Mutations have been ide...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A  Single-center Experience
Conclusion Ibrutinib is a highly effective and tolerable drug for B-cell malignancies in the general community. In contrast to the previously reported rate of 5% to 7%, we observed a higher rate (11%) of atrial fibrillation, which might have resulted from the smaller sample size in the present study and the multiple comorbidities. Nonetheless, this treatment-limiting side effect requires further elucidation. Paradoxical lymphocytosis at the outset of therapy was a common and benign finding. In conjunction with the reported trials, the IgG levels decreased in the first year of continued therapy. However, the IgA levels did ...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Developmental Therapeutics in Myeloproliferative Neoplasms
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Prithviraj Bose, Srdan Verstovsek The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis (MF) provided much-needed impetus for clinical drug development for the Philadelphia chromosome–negative myeloproliferative neoplasms. The survival benefit conferred by this agent, along with its marked efficacy with regard to spleen volume and symptom reduction, have made ruxolitinib the cornerstone of drug therapy in MF. However, there remain significant unmet needs in the treatmen...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms
We describe the challenges of the appropriate diagnosis and treatment of MDS/MPN. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

First-line Therapeutic Strategies for Myelodysplastic Syndromes
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Valeria Santini The precise diagnostic tests and subsequent prognostic stratification for patients with myelodysplastic syndrome (MDS) are often cumbersome, yet they are the basis of successful therapy. Diverse treatment options are available for these patients; however, the decisions in real-life are often not grounded on the available evidence. Although the International Prognostic Scoring System and revised International Prognostic Scoring System are still driving the medical approach to MDS patients, additional ...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): David A. Sallman, Marco L. Davila Myelodysplastic syndromes (MDSs) and related myeloid neoplasms represent heterogeneous diseases with overall poor outcomes related to lack of efficacious agents. Immunotherapy has revolutionized the treatment paradigm in solid malignancies and select hematologic malignancies with durable remissions in treatment-refractory populations. The initial clinical studies using immunotherapy in MDS are under way, although significant efforts are required in which to better understand their r...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune  Checkpoints
Conclusion BM morphology and PD-L1 expression by immunohistochemistry can be used to assess treatment response in immune checkpoints therapy. Micro-Abstract In MDS, hypomethylating agents (HMA) failure is related to poor outcome. HMA up-regulates immune checkpoints in blasts. We describe the clinicopathologic correlations in an MDS patient treated with PD-1 inhibitor and assessed PD-L1 expression in bone marrow (BM). BM morphology and PD-L1 expression by immunohistochemistry can be used to assess treatment response. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Philadelphia-positive Acute Lymphoblastic Leukemia: Do We Still Need Allogeneic Transplantation? Argument “Pro”
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Veronika Bachanova (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Renato Bassan, Tamara Intermesoli, Annamaria Scattolin, Piera Viero, Elena Maino, Rosaria Sancetta, Francesca Carobolante, Francesca Gianni, Paola Stefanoni, Manuela Tosi, Orietta Spinelli, Alessandro Rambaldi The study of minimal residual disease (MRD) in adult patients with acute lymphoblastic leukemia (ALL) allows a greater refinement of the individual risk classification and is the best support for risk-specific therapy with or without allogeneic hematopoietic cell transplantation (HCT). Using case-specific sens...
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Proceedings of the Fourth Annual Meeting of the Society of Hematologic Oncology
Publication date: July 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Supplement Author(s): Society of Hematologic Oncology (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 29, 2017 Category: Cancer & Oncology Source Type: research

Effect of Routine Surveillance Imaging on the Outcomes of Patients With Classical Hodgkin Lymphoma After Autologous Hematopoietic Cell Transplantation
Conclusion A minority of patients with cHL who achieve CR after auto-HCT will ultimately relapse. Surveillance imaging detected approximately half of relapses; however, outcomes were similar for those whose relapse was detected using routine surveillance imaging versus detected clinically in between surveillance imaging studies. There appears to be limited utility for routine surveillance imaging in cHL patients who achieve CR after auto-HCT. Micro-Abstract Surveillance imaging is often used following autologous hematopoietic cell transplantation (auto-HCT) to assess for relapse. We evaluated classical Hodgkin lymphoma (cH...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2017 Category: Cancer & Oncology Source Type: research

Sepsis and Acute Myeloid Leukemia: A Population Level Study of Comparative Outcomes of Patients Discharged from Texas Hospitals
Conclusions Patients with AML had a higher sepsis incidence and higher mortality rates overall, especially in relation to stem cell transplant patients and those with other types of cancer. Clinical trials are needed to determine whether early interventions or treatment in specialized centers could improve outcomes and reduce costs of care, particularly in the management of serious complications such as sepsis. Teaser We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of > 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsis-relate...
Source: Clinical Lymphoma Myeloma and Leukemia - July 25, 2017 Category: Cancer & Oncology Source Type: research

The clinical spectrum of hepatic manifestations in chronic lymphocytic leukemia
Publication date: Available online 23 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Natalia Kreiniz, Ofrat Beyar Katz, Aaron Polliack, Tamar Tadmor Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world, characterized by the presence of long-lived circulating leukemic cells in the peripheral blood which may infiltrate all organs, particularly those of the reticulo- endothelial system. Liver enlargement and elevation of liver enzymes related to specific involvement by the underlying disease are well-recognized features in these patients. In CLL the differential diagnosis of...
Source: Clinical Lymphoma Myeloma and Leukemia - July 23, 2017 Category: Cancer & Oncology Source Type: research

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
Conclusion Among the eight signatures, SKY92 identified the largest proportion of patients (21%) also with the highest HR (8.2). Our analysis also validated the combination SKY92/ISS for identification of three classes; low risk (42%), intermediate risk (37%) and high risk (21%). Between low risk and high risk classes the HR is >10. Micro-Abstract An independent dataset of 91 multiple myeloma patients were tested with eight prognostic mRNA expression signatures. SKY92 best predicted survival (HR = 8.2) and classified the largest fraction (21%) as high risk. Finally 38/91 (42%) cases were low risk by the recently pro...
Source: Clinical Lymphoma Myeloma and Leukemia - July 21, 2017 Category: Cancer & Oncology Source Type: research

Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review
Publication date: Available online 21 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Anthony R. Mato, Meghan C. Thompson, Chadi Nabhan, Jakub Svoboda, Stephen J. Schuster The treatment landscape for chronic lymphocytic leukemia (CLL) is changing rapidly. Novel targeted agents such as ibrutinib, venetoclax and idelalisib have made a significant impact on both first line, relapsed/refractory, and high-risk disease. Despite these advances, there are continuous needs for new treatment options, especially for patients who fail or cannot tolerate these novel therapies. In 2011, Porter et al reported the firs...
Source: Clinical Lymphoma Myeloma and Leukemia - July 21, 2017 Category: Cancer & Oncology Source Type: research

Extrafollicular PD1 and Intrafollicular CD3 Expression Are Associated With Survival in Follicular Lymphoma
Conclusion Our study supports the hypothesis that survival in FL depends on the immunologic cross talk between malignant cells and microenvironment; however, the specific types of cells that influence the clinical behavior of FL are still unknown. Micro-Abstract This study aimed to stratify follicular lymphoma (FL) patients' outcome according to immunohistochemical parameters. The study correlated Ki-67, CD68, PD1 and CD3 results with clinical outcome. We found that high extrafollicular PD1 and low intrafollicular CD3 correlated with better outcome. Further studies are necessary in order to understand the complexity of the...
Source: Clinical Lymphoma Myeloma and Leukemia - July 19, 2017 Category: Cancer & Oncology Source Type: research

Time to second-line treatment and subsequent relative survival in older patients with relapsed CLL/SLL
Publication date: Available online 19 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Eric M. Ammann, Tait D. Shanafelt, Melissa C. Larson, Kara B. Wright, Bradley D. McDowell, Brian K. Link, Elizabeth A. Chrischilles Novel targeted therapies offer excellent short-term outcomes in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). However, there is disagreement over how widely these therapies should be used in place of standard chemo-immunotherapy (CIT). We investigated whether stratification on the length of the interval between first-line (T1) and second-line (T2) tre...
Source: Clinical Lymphoma Myeloma and Leukemia - July 19, 2017 Category: Cancer & Oncology Source Type: research

Cardiovascular Events after Exposure to Nilotinib in Chronic Myeloid Leukemia: Long Term Follow up
Conclusion The incidence of CVEs and frequency of asymptomatic PAD in this population was low and CVEs were associated with cardiovascular risk factors. Aggressive risk factor modification and applying standard definitions for measuring cardiovascular outcomes, might have contributed to the result. Further prospective and adequately powered studies are needed to explore the effect of cardiovascular risk profile on CVEs in CML patients on Nilotinib. Teaser This study evaluated the incidence of cardiovascular events (CVEs) in 63 chronic myeloid leukemia (CML) patients after long term exposure to Nilotinib. By considering the...
Source: Clinical Lymphoma Myeloma and Leukemia - July 15, 2017 Category: Cancer & Oncology Source Type: research

Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy
Conclusion Our results have shown that middle-age patients have the best clinical outcomes, with the greatest rates of an optimal therapeutic response, longer event-free survival, and longer overall survival. Micro-Abstract The present study investigated the outcomes in different age groups of 101 patients receiving front-line imatinib therapy for chronic myeloid leukemia. Middle-age patients had a significantly greater rate of major molecular response, a superior estimated 6-year event-free survival, and a greater estimated 6-year overall survival rate compared with younger and elderly patients and, consequently, the best...
Source: Clinical Lymphoma Myeloma and Leukemia - July 14, 2017 Category: Cancer & Oncology Source Type: research

Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies
Publication date: Available online 14 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Julia D. Ransohoff, Bernice Y. Kwong The identification of oncogenic drivers of liquid tumors has led to the rapid development of targeted agents with distinct cutaneous adverse event (AE) profiles. The diagnosis and management of these skin toxicities has motivated a novel partnership between dermatologists and oncologists in developing supportive oncodermatology clinics. Here we review the current state of knowledge of clinical presentation, mechanisms, and management of the most common and significant cutaneous AEs ...
Source: Clinical Lymphoma Myeloma and Leukemia - July 14, 2017 Category: Cancer & Oncology Source Type: research

Long Term Outcomes of Hairy Cell Leukemia Treated with Purine Analogs: a Comparison to the General Population
Publication date: Available online 14 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Yazan F. Madanat, Lisa Rybicki, Tomas Radivoyevitch, Deepa Jagadeesh, Robert Dean, Brad Pohlman, Matt Kalaycio, Mikkael A. Sekeres, Mitchell R. Smith, Brian T. Hill Hairy Cell Leukemia (HCL) is a rare hematologic malignancy with high response rates and long progression-free survival (PFS) after treatment with purine nucleoside analogs [PNAs; Pentostatin/ Cladribine]. However, treatment is not curative and subsequent treatment at relapse is often required. Re-challenge with a purine analog is commonly implemented despit...
Source: Clinical Lymphoma Myeloma and Leukemia - July 14, 2017 Category: Cancer & Oncology Source Type: research

Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto
Conclusion Bath PUVA and nbUVB are both effective treatments. The use of bath PUVA resulted in significantly greater disease-free survival. Micro-Abstract Phototherapy is one of the mainstay treatments for early stages mycosis fungoides (MF). Response rates are not statistically different when utilizing either bath PUVA or nbUVB in early stage MF. However, longer remission is achieved with bath PUVA therapy. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 13, 2017 Category: Cancer & Oncology Source Type: research

Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era
Conclusion We conclude that outcomes for FL grade 3, primarily treated with R-CHOP, do not differ between FL3A and aggFL (FL3B and FL3/DLBCL). The aggFL group showed a plateau in PFS confirming these should be treated with curative intent. FL3A patients, mainly managed with R-CHOP, also show an apparent plateau in PFS. While longer follow-up and confirmation in other datasets is required, this indicates potential under-treatment of FL3A with less aggressive regimens often used for indolent lymphoma. Teaser Whether to clinically approach follicular lymphoma (FL) grade 3 as an indolent or aggressive lymphoma, especially sinc...
Source: Clinical Lymphoma Myeloma and Leukemia - July 13, 2017 Category: Cancer & Oncology Source Type: research

Characteristics of vitamin B12 deficiency in patients with plasma cell disorders
Conclusion Higher FLC burden was associated with poor kidney function but not with low B12. Low B12 was seen more commonly in patients with preserved kidney function. MCV was statistically but not clinically different between low and normal B12 patients and, therefore, may not be a reliable indicator of B12 deficiency in PCDs. Prospective studies should compare B12 metabolites with FLC levels. Detection of B12 deficiency among PCD patients remains important to reduce neurologic dysfunction and cytopenias, sequelae common to B12 deficiency and PCDs. Teaser Vitamin B12 deficiency is prevalent among patients with plasma cell ...
Source: Clinical Lymphoma Myeloma and Leukemia - July 12, 2017 Category: Cancer & Oncology Source Type: research

What is the role of chemotherapy in patients with chronic lymphocytic leukemia?
Publication date: Available online 12 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Bruce D. Cheson The current standard treatment for patients with chronic lymphocytic leukemia (CLL) who require therapy is chemoimmunotherapy. However, the availability of an increasing number of targeted agents and combination warrants a reassessment of that approach. The high rate of durable responses with ibrutinib in relapsed refractory patients has established its role in this setting; however, because of its impressive efficacy as initial treatment, it should be considered as part of the algorithm in appropriate ...
Source: Clinical Lymphoma Myeloma and Leukemia - July 12, 2017 Category: Cancer & Oncology Source Type: research

Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study
Conclusion Compared with fosaprepitant, olanzapine reduced the number of patients with acute (P < .0318) and delayed (P < .1519) nausea and reduced the need for rescue medications for acute-onset (P < .0643) and delayed-onset (P < .0024) CINV. Micro-Abstract Chemotherapy-induced nausea and vomiting (CINV) is common in patients who receive high-dose melphalan as a conditioning regimen before autologous hematopoietic stem cell transplantation. With suboptimal CINV control using an aprepitant-based antiemetic regimen, we switched to an olanzapine-based regimen. We performed a re...
Source: Clinical Lymphoma Myeloma and Leukemia - July 8, 2017 Category: Cancer & Oncology Source Type: research

Acute Promyelocytic Leukemia: A perspective
Publication date: Available online 6 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Farhad Ravandi, Richard Stone (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 6, 2017 Category: Cancer & Oncology Source Type: research

Evaluation of bortezomib induced neuropathy using Total Neuropathy Score (reduced and clinical versions) and NCI CTCAE v4.0 in newly diagnosed patients with multiple myeloma receiving bortezomib-based induction
Conclusions NCI-CTCAE may be suboptimal in comparison to TNSr and TNSc in assessment of BiPN as it may miss worsening neuropathy without functional limitation. Teaser Total Neuropathy Score (TNS) (reduced and clinical versions) is ideal for evaluation of bortezomib induced neuropathy. We used TNSr and TNSc along with NCI CTCAE v4.0 to assess incidence of neuropathy in patients receiving CyBorD as induction for multiple myeloma. Out of 20 evaluable patients, 55%, 40% and 45% developed neuropathy when assessed by TNSr, TNSc and NCI CTCAE respectively. We found wide variation in TNSr and TNSc even when NCI CTCAE scale reporte...
Source: Clinical Lymphoma Myeloma and Leukemia - July 6, 2017 Category: Cancer & Oncology Source Type: research

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Conclusion This study furthers implementation of clinical genomics in MDS and identifies TP53 and IDH2 as targets for pre- or post-transplant therapy. Micro-Abstract Allogeneic hematopoietic cell transplantation represents the only treatment option capable of offering a cure to patients with myelodysplastic syndrome. Here, we demonstrate that presence of mutations in TP53 and IDH2 in myelodysplastic syndrome confer a poor prognosis even in the setting of allogeneic transplantation. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 5, 2017 Category: Cancer & Oncology Source Type: research

Prognostic validation of SKY92 and its combination with ISS in an independent cohort of Multiple Myeloma patients
Publication date: Available online 4 July 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Erik H. van Beers, Martin H. van Vliet, Rowan Kuiper, Leonie de Best, Kenneth C. Anderson, Ajai Chari, Sundar Jagannath, Andrzej Jakubowiak, Shaji K. Kumar, Joan B. Levy, Daniel Auclair, Sagar Lonial, Donna Reece, Paul Richardson, David S. Siegel, A. Keith Stewart, Suzanne Trudel, Ravi Vij, Todd M. Zimmerman, Rafael Fonseca (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 4, 2017 Category: Cancer & Oncology Source Type: research

Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma
Conclusion A preparative regimen of PK-directed IV Bu with Btz and Mel led to an ORR of 100% with acceptable toxicity and should be considered for direct comparison with the Mel200 regimen in future trials. Micro-Abstract We explored safety and efficacy of the combination of pharmacokinetics-directed busulfan, melphalan and bortezomib as conditioning regimen for autologous stem cell transplantation in multiple myeloma. In this prospective phase II trial, 19 patients were treated and achieved an overall response rate of 100% and a 2-year progression-free survival and overall survival of 57.9% and 88.5% respectively with acc...
Source: Clinical Lymphoma Myeloma and Leukemia - July 3, 2017 Category: Cancer & Oncology Source Type: research

Proteasome Subunit Beta Type 1 P11A polymorphism is a new prognostic marker in multiple myeloma
Conclusion Our results show that carriership of PSMB1 rs12717 minor allele is predictive for suboptimal response with bortezomib treatment, which could be explained by less active proteasomes which are less sensitive to bortezomib, and myeloma cells consequently relying on other escape mechanism to cope with the abundance of misfolded proteins. Teaser We retrospectively analyzed the prognostic impact of Proteasome subunit beta type 1 rs12717 polymorphism in 211 consecutively diagnosed multiple myeloma cases. Patients carrying the variant G allele showed significantly shorter progression free survival. In proteasomes of ind...
Source: Clinical Lymphoma Myeloma and Leukemia - June 30, 2017 Category: Cancer & Oncology Source Type: research

Defibrotide use in vincristine induced hepatic sinusoidal obstruction syndrome
Publication date: Available online 30 June 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Catherine Tang, Julian Lindsay, Anthony Gill, Ian Kerridge (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 30, 2017 Category: Cancer & Oncology Source Type: research

Extended Follow up of Patients Treated with Bendamustine for Lymphoid Malignancies
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Teaser Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. In order to determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 30, 2017 Category: Cancer & Oncology Source Type: research

How to Approach a Patient with Limited Stage Hodgkin Lymphoma Who Remains PET Positive at the End of Chemotherapy: Radiation Therapy?
Publication date: Available online 29 June 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Nmazuo W. Ozuah, Ann S. LaCasce The use of 18 F-fluorodeoxyglucose positron emission tomography with computerized tomography (FDG-PET/CT), has emerged as a crucial tool for response-adapted therapy in Hodgkin lymphoma (HL). Although more studies have focused on the predictive value of an interim or early PET obtained after 2 cycles of chemotherapy, there are indications that the end of therapy PET may even be more predictive of outcome. The optimal treatment of patients with limited stage HL who are PET positive after ...
Source: Clinical Lymphoma Myeloma and Leukemia - June 29, 2017 Category: Cancer & Oncology Source Type: research

The role of low-dose anti-thymocyte globulin as standard prophylaxis in mismatched and matched unrelated hematopoietic peripheral stem cell transplantation for hematologic malignancies
Conclusion A relatively low-dose ATG is effective in acute GVHD prophylaxis leading to promising survival rates in matched transplants. Further comparative studies with adjusted ATG dose depending on HLA disparity or alternative donors are warranted. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 29, 2017 Category: Cancer & Oncology Source Type: research

Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study
Conclusions Although the presence of severe comorbidities was lower when assessed by ACE-27 (13%) compared to HCT-CI (23%), and the spectrums of comorbidities captured were different, the overall impact of severe comorbidities as assessed by both scales appears to be similar and associated with a survival disadvantage. Teaser In a retrospective study of 309 patients with myelofibrosis (MF), severe burden of comorbidities as assessed by the Adult Comorbidity Evaluation 27 (ACE-27) or Hematopoietic Cell Transplant Comorbidity Index (HCT-CI) was associated with worse overall survival. ACE-27 may be preferred for comorbidity a...
Source: Clinical Lymphoma Myeloma and Leukemia - June 29, 2017 Category: Cancer & Oncology Source Type: research

Effectiveness of single-dose rasburicase in patients with lymphoid malignancies at a high risk for tumor lysis syndrome
Conclusion Our data indicated that single-dose rasburicase effectively prevented progression of TLS, and regardless of within any risk factors including of increased creatinine, single-dose rasburicase for TLS prophylaxis was useful in patient with lymphoma at a high risk for TLS. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 27, 2017 Category: Cancer & Oncology Source Type: research

Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future
Publication date: Available online 27 June 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Daniel W. Sherbenou, Tomer M. Mark, Peter Forsberg In 2015, two monoclonal antibodies were approved for the treatment of relapsed or refractory multiple myeloma (RRMM), elotuzumab and daratumumab. Elotuzumab is a monoclonal IgG-κ antibody directed against SLAMF7, a cell surface receptor involved in natural killer cell activation. Daratumumab is a monoclonal IgG-κ antibody that binds to CD38, a transmembrane protein found on the surface of myeloma cells responsible for cellular adhesion and ectoenzymatic act...
Source: Clinical Lymphoma Myeloma and Leukemia - June 27, 2017 Category: Cancer & Oncology Source Type: research

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma
Conclusion Further evaluation of PLD, bortezomib, and deacetylase inhibitor combinations is warranted, with special attention directed toward strategies to improve tolerability. Micro-Abstract We evaluated the combination of pegylated liposomal doxorubicin, bortezomib and vorinostat in 32 patients with relapsed/refractory multiple myeloma in a phase I study. The maximum tolerated dose of vorinostat with PLD/bortezomib was 400 mg on days 4 to 11. Clinical activity was seen including in bortezomib-refractory patients. However, hematologic, constitutional and gastrointestinal toxicity was common. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 25, 2017 Category: Cancer & Oncology Source Type: research

Annual Facility Treatment Volume and Patient Survival for Mycosis Fungoides and S ézary Syndrome
Conclusion The present national database analysis demonstrated that higher facility ATV is associated with improved OS for patients with MF/SS. Further study is needed to determine the underlying reasons for improved survival with higher facility ATV. Micro-Abstract Mycosis fungoides and Sézary syndrome (MF/SS) management is complex, with heterogeneous treatments. We analyzed a national registry of > 2200 MF/SS patients divided into cohorts by the annual treatment volume quintile of their treatment facility. A greater facility annual treatment volume was associated with improved survival for patients with MF/...
Source: Clinical Lymphoma Myeloma and Leukemia - June 24, 2017 Category: Cancer & Oncology Source Type: research